Abstract PS3-11-08: Subcutaneous pertuzumab and trastuzumab fixed-dose combination versus dual intravenous pertuzumab and trastuzumab or subcutaneous trastuzumab plus intravenous pertuzumab in HER2-positive breast cancer adjuvant therapy: A time and motion study in a lean operating day care oncology unit in China
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Shandong First Medical University, Shandong Tumor Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129549684
Cites:
Cited by:
Related to: